Abstract
Recognition of aberrant gene isoforms indicative of underlying DNA events can impact molecular classification and risk stratification of B lymphoblastic leukemia (B-ALL). Aberrant ERG isoforms have been proposed as markers of the favorable-risk DUX4-rearranged (DUX4r) subtype while deletion-mediated IKZF1 isoforms are associated with adverse prognosis in non-DUX4r B-ALL. The high-risk IKZF1plus signature depends on gene deletions including PAX5 while intragenic PAX5 amplifications (PAX5amp) are recurrent in the provisional B-ALL with PAX5-alteration subtype. In this study, we screened for outlier expression of isoforms within targeted RNA sequencing assays designed for fusions. Outlier analysis of known and novel IKZF1, ERG, and PAX5 isoforms was 97.0% (32/33), 90% (9/10), and 100% (6/6) sensitive and 97.8% (226/231), 100% (35/35), and 88.5% (23/26) specific for IKZF1 intragenic or 3’ deletions, DUX4r, and PAX5 intragenic deletions respectively, where false positives were favored to represent low-level deletions below the limit of DNA-based detection. Outlier analysis also identified putative PAX5amp cases and revealed partial tandem duplication (PTD) spanning IKZF1 N159Y in the B-ALL with mutated N159Y subtype. To demonstrate utility in other tumor types, outlier analysis was 100% (9/9) sensitive and 100% (255/255) specific for KMT2A-PTD in hematologic samples and 100% (7/7) sensitive and 100% (79/79) specific for FGFR1 tyrosine kinase domain duplication in brain tumors. These findings support the use of aberrant isoform analysis in targeted RNA sequencing data as a robust strategy for the detection of clinically significant DNA events.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by a St. Baldrick's Foundation Consortium grant (YP), Charles H. Hood Foundation Grant (YP), and NIH K08 CA222684 (YP).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Boston Children's Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data produced in the present study are available upon reasonable request to the authors.
